Advertisement

Connexin43 hemichannel block protects against the development of diabetic retinopathy signs in a mouse model of the disease

  • Odunayo O. Mugisho
  • Colin R. Green
  • David M. Squirrell
  • Sarah Bould
  • Helen V. Danesh-Meyer
  • Jie Zhang
  • Monica L. Acosta
  • Ilva D. Rupenthal
Original Article
  • 56 Downloads

Abstract

Diabetic retinopathy (DR) is a vascular disease of the neuroretina characterised by hyperglycaemia and inflammation. Current DR therapies target late-stage vascular defects and there is evidence to suggest that they contribute to geographic atrophy and retinal ganglion cell death long term. Therefore, alternative treatments that target common upstream disease mechanisms are needed. Recent studies have shown that connexin43 hemichannel blockers can reduce inflammation and prevent vessel leak in brain and spinal cord lesions. The aim of this study was to evaluate the effectiveness of a connexin43 hemichannel blocker (Peptide5) in a mouse model of DR in which pro-inflammatory cytokines, IL-1β and TNF-α, were intravitreally injected into non-obese diabetic (NOD, hyperglycaemic) mice. Fundus and optical coherence tomography images were taken to evaluate vessel dilation and beading as well as retinal and vitreous hyper-reflective foci (HRF). Immunohistochemistry was performed to assess levels of astrogliosis, microgliosis and inflammasome activation. Results showed that Peptide5 injection lowered the incidence of vessel dilation and beading, decreased the severity of vitreous and retinal HRF, and reduced sub-retinal fluid accumulation compared to the vehicle group. Furthermore, Peptide5 led to reduced connexin43 and GFAP upregulation, inhibited microglial infiltration into the outer nuclear layer and prevented upregulation of inflammasome markers compared to vehicle. The present study provides evidence in support of Peptide5, and connexin43 hemichannel block in general, as a potential upstream approach for the treatment of DR.

Key messages

  • Connexin43 is upregulated in a novel mouse model of diabetic retinopathy (DR).

  • Connexin43 hemichannel block inhibits inflammation and inflammasome activation.

  • Connexin43 hemichannel block prevents the development of clinical DR signs.

  • Connexin43 hemichannel block is a potential upstream approach for DR treatment.

Keywords

Diabetic retinopathy Mouse models Connexin43 Hemichannels Inflammation 

Notes

Acknowledgements

O.O.M. was supported by a doctoral scholarship from the Buchanan Ocular Therapeutics Unit, University of Auckland, New Zealand.

Funding information

The study was partially funded by a Lottery Health Research Grant, Department of Internal Affairs, and an Auckland Medical Research Foundation Grant [1117015], New Zealand. C.R.G. holds the W&B Hadden Chair in Ophthalmology.

References

  1. 1.
    Abu el Asrar AM, Maimone D, Morse PH, Gregory S, Reder AT (1992) Cytokines in the vitreous of patients with proliferative diabetic retinopathy. Am J Ophthalmol 114(6):731–736CrossRefPubMedGoogle Scholar
  2. 2.
    Tang J, Kern TS (2011) Inflammation in diabetic retinopathy. Prog Retin Eye Res 30(5):343–358CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Zhou J, Wang S, Xia X (2012) Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy. Curr Eye Res 37(5):416–420CrossRefPubMedGoogle Scholar
  4. 4.
    Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd, Comparison of Age-related Macular Degeneration Treatments Trials Research G (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119(7):1388–1398CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Gemenetzi M, Lotery AJ, Patel PJ (2017) Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents. Eye (Lond) 31(1):1–9CrossRefGoogle Scholar
  6. 6.
    Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, Fine SL, Blodi B, Klein ML, Martin AA, Hagstrom SA, Martin DF, Group CR (2014) Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 121(1):150–161CrossRefPubMedGoogle Scholar
  7. 7.
    Nishijima K, Ng YS, Zhong LC, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT (2007) Vascular endothelial growth factor-a is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171(1):53–67CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Mori R, Power KT, Wang CHM, Martin P, Becker DL (2006) Acute downregulation of connexin43 at wound sites leads to a reduced inflammatory response, enhanced keratinocyte proliferation and wound fibroblast migration. J Cell Sci 119(24):5193–5203CrossRefPubMedGoogle Scholar
  9. 9.
    Oviedo-Orta E, Kwak BR, Evans WH (2013) Connexin cell communication channels: roles in the immune system and immunopathology. CRC Press, Boca RatonCrossRefGoogle Scholar
  10. 10.
    Qiu C, Coutinho P, Frank S, Franke S, Law L-y, Martin P, Green CR, Becker DL (2003) Targeting connexin43 expression accelerates the rate of wound repair. Curr Biol 13(19):1697–1703CrossRefPubMedGoogle Scholar
  11. 11.
    Danesh-Meyer HV, Zhang J, Acosta ML, Rupenthal ID, Green CR (2016) Connexin43 in retinal injury and disease. Prog Retin Eye Res 51:41–68CrossRefPubMedGoogle Scholar
  12. 12.
    Leybaert L, Lampe PD, Dhein S, Kwak BR, Ferdinandy P, Beyer EC, Laird DW, Naus CC, Green CR, Schulz R (2017) Connexins in cardiovascular and neurovascular health and disease: pharmacological implications. Pharmacol Rev 69(4):396–478CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Danesh-Meyer HV, Kerr NM, Zhang J, Eady EK, O'Carroll SJ, Nicholson LF, Johnson CS, Green CR (2012) Connexin43 mimetic peptide reduces vascular leak and retinal ganglion cell death following retinal ischaemia. Brain 135(Pt 2):506–520CrossRefPubMedGoogle Scholar
  14. 14.
    Willebrords J, Crespo Yanguas S, Maes M, Decrock E, Wang N, Leybaert L, Kwak BR, Green CR, Cogliati B, Vinken M (2016) Connexins and their channels in inflammation. Crit Rev Biochem Mol Biol 51(6):413–439CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Bennett MV, Garre JM, Orellana JA, Bukauskas FF, Nedergaard M, Saez JC (2012) Connexin and pannexin hemichannels in inflammatory responses of glia and neurons. Brain Res 1487:3–15CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Decrock E, De Bock M, Wang N, Bultynck G, Giaume C, Naus CC, Green CR, Leybaert L (2015) Connexin and pannexin signaling pathways, an architectural blueprint for CNS physiology and pathology? Cell Mol Life Sci 72(15):2823–2851CrossRefPubMedGoogle Scholar
  17. 17.
    Kim Y, Davidson JO, Gunn KC, Phillips AR, Green CR, Gunn AJ (2016) Role of hemichannels in CNS inflammation and the inflammasome pathway. Adv Protein Chem Struct Biol 104:1–37CrossRefPubMedGoogle Scholar
  18. 18.
    De Bock M, Culot M, Wang N, Bol M, Decrock E, De Vuyst E, da Costa A, Dauwe I, Vinken M, Simon AM, Rogiers V, De Ley G, Evans WH, Bultynck G, Dupont G, Cecchelli R, Leybaert L (2011) Connexin channels provide a target to manipulate brain endothelial calcium dynamics and blood-brain barrier permeability. J Cereb Blood Flow Metab 31(9):1942–1957CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    O'Carroll SJ, Alkadhi M, Nicholson LF, Green CR (2008) Connexin 43 mimetic peptides reduce swelling, astrogliosis, and neuronal cell death after spinal cord injury. Cell Commun Adhes 15(1):27–42CrossRefPubMedGoogle Scholar
  20. 20.
    Wang N, De Vuyst E, Ponsaerts R, Boengler K, Palacios-Prado N, Wauman J, Lai CP, De Bock M, Decrock E, Bol M, Vinken M, Rogiers V, Tavernier J, Evans WH, Naus CC, Bukauskas FF, Sipido KR, Heusch G, Schulz R, Bultynck G, Leybaert L (2013) Selective inhibition of Cx43 hemichannels by Gap19 and its impact on myocardial ischemia/reperfusion injury. Basic Res Cardiol 108(1):309CrossRefPubMedGoogle Scholar
  21. 21.
    Davidson JO, Green CR, Nicholson LF, O'Carroll SJ, Fraser M, Bennet L, Gunn AJ (2012) Connexin hemichannel blockade improves outcomes in a model of fetal ischemia. Ann Neurol 71(1):121–132CrossRefPubMedGoogle Scholar
  22. 22.
    Galinsky R, Davidson J, Bennet L, Green C, Gunn A (2015) Connexin Hemichannel blockade improves survival of striatal neurons after perinatal cerebral Ischaemia. J Paediatr Child Health 51:60Google Scholar
  23. 23.
    Mao Y, Tonkin RS, Nguyen T, O'Carroll SJ, Nicholson LF, Green CR, Moalem-Taylor G, Gorrie CA (2017) Systemic administration of Connexin43 mimetic peptide improves functional recovery after traumatic spinal cord injury in adult rats. J Neurotrauma 34(3):707–719CrossRefPubMedGoogle Scholar
  24. 24.
    O'Carroll SJ, Gorrie CA, Velamoor S, Green CR, Nicholson LF (2013) Connexin43 mimetic peptide is neuroprotective and improves function following spinal cord injury. Neurosci Res 75(3):256–267CrossRefPubMedGoogle Scholar
  25. 25.
    Orellana JA, Froger N, Ezan P, Jiang JX, Bennett MV, Naus CC, Giaume C, Saez JC (2011) ATP and glutamate released via astroglial connexin 43 hemichannels mediate neuronal death through activation of pannexin 1 hemichannels. J Neurochem 118(5):826–840CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Ormonde S, Chou CY, Goold L, Petsoglou C, Al-Taie R, Sherwin T, McGhee CN, Green CR (2012) Regulation of connexin43 gap junction protein triggers vascular recovery and healing in human ocular persistent epithelial defect wounds. J Membr Biol 245(7):381–388CrossRefPubMedGoogle Scholar
  27. 27.
    Guo CX, Mat Nor MN, Danesh-Meyer HV, Vessey KA, Fletcher EL, O'Carroll SJ, Acosta ML, Green CR (2016) Connexin43 mimetic peptide improves retinal function and reduces inflammation in a light-damaged albino rat model. Invest Ophthalmol Vis Sci 57(10):3961–3973CrossRefPubMedGoogle Scholar
  28. 28.
    Kim Y, Griffin JM, Harris PW, Chan SH, Nicholson LF, Brimble MA, O'Carroll SJ, Green CR (2017) Characterizing the mode of action of extracellular Connexin43 channel blocking mimetic peptides in an in vitro ischemia injury model. Biochim Biophys Acta 1861(2):68–78CrossRefGoogle Scholar
  29. 29.
    Mugisho OO, Rupenthal ID, Squirrell DM, Bould SJ, Danesh-Meyer HV, Zhang J, Green CR, Acosta ML (2018) Intravitreal pro-inflammatory cytokines in non-obese diabetic mice: modelling signs of diabetic retinopathy. PLoS One 13(8):e0202156.  https://doi.org/10.1371/journal.pone.0202156 CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Mugisho OO, Green CR, Kho DT, Zhang J, Graham ES, Acosta ML, Rupenthal ID (2018) The inflammasome pathway is amplified and perpetuated in an autocrine manner through connexin43 hemichannel mediated ATP release. Biochim Biophys Acta 1862(3):385–393CrossRefGoogle Scholar
  31. 31.
    Mugisho OO, Green CR, Zhang J, Binz N, Acosta ML, Rakoczy E, Rupenthal ID (2017) Immunohistochemical characterization of connexin43 expression in a mouse model of diabetic retinopathy and in human donor retinas. Int J Mol Sci 18(12):2567CrossRefPubMedCentralGoogle Scholar
  32. 32.
    Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS, Kester M, Kimball SR, Krady JK, LaNoue KF, Norbury CC, Quinn PG, Sandirasegarane L, Simpson IA, Group JDRC (2006) Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 55(9):2401–2411CrossRefPubMedGoogle Scholar
  33. 33.
    Coscas G, Lupidi M, Coscas F (2017) OCT-A: guided treatment of diabetic retinopathy. Acta Ophthalmol 95(S259)Google Scholar
  34. 34.
    Mizukami T, Hotta Y, Katai N (2017) Higher numbers of hyperreflective foci seen in the vitreous on spectral-domain optical coherence tomographic images in eyes with more severe diabetic retinopathy. Ophthalmologica 238(1–2):74–80CrossRefPubMedGoogle Scholar
  35. 35.
    Ferris FL 3rd, Patz A (1984) Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol 28(Suppl):452–461CrossRefPubMedGoogle Scholar
  36. 36.
    Chen YS, Green CR, Wang K, Danesh-Meyer HV, Rupenthal ID (2015) Sustained intravitreal delivery of connexin43 mimetic peptide by poly(D,L-lactide-co-glycolide) acid micro- and nanoparticles--closing the gap in retinal ischaemia. Eur J Pharm Biopharm 95(Pt B):378–386CrossRefPubMedGoogle Scholar
  37. 37.
    Chen YS, Green CR, Teague R, Perrett J, Danesh-Meyer HV, Toth I, Rupenthal ID (2015) Intravitreal injection of lipoamino acid-modified connexin43 mimetic peptide enhances neuroprotection after retinal ischemia. Drug Deliv Transl Res 5(5):480–488CrossRefPubMedGoogle Scholar
  38. 38.
    Kerr NM, Johnson CS, de Souza CF, Chee KS, Good WR, Green CR, Danesh-Meyer HV (2010) Immunolocalization of gap junction protein connexin43 (GJA1) in the human retina and optic nerve. Invest Ophthalmol Vis Sci 51(8):4028–4034CrossRefPubMedGoogle Scholar
  39. 39.
    Simo-Servat O, Hernandez C, Simo R (2012) Usefulness of the vitreous fluid analysis in the translational research of diabetic retinopathy. Mediat Inflamm 2012:872978:1–11CrossRefGoogle Scholar
  40. 40.
    Urbancic M, Kloboves Prevodnik V, Petrovic D, Globocnik Petrovic M (2013) A flow cytometric analysis of vitreous inflammatory cells in patients with proliferative diabetic retinopathy. Biomed Res Int 2013:251528CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Feit-Leichman RA, Kinouchi R, Takeda M, Fan Z, Mohr S, Kern TS, Chen DF (2005) Vascular damage in a mouse model of diabetic retinopathy: relation to neuronal and glial changes. Invest Ophthalmol Vis Sci 46(11):4281–4287CrossRefPubMedGoogle Scholar
  42. 42.
    Fletcher EL, Phipps JA, Ward MM, Puthussery T, Wilkinson-Berka JL (2007) Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy. Curr Pharm Des 13(26):2699–2712CrossRefPubMedGoogle Scholar
  43. 43.
    Rungger–Brändle E, Dosso AA, Leuenberger PM (2000) Glial reactivity, an early feature of diabetic retinopathy. Invest Ophthalmol Vis Sci 41(7):1971–1980PubMedGoogle Scholar
  44. 44.
    El-Asrar AM (2012) Role of inflammation in the pathogenesis of diabetic retinopathy. Middle East Afr J Ophthalmol 19(1):70–74CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Chaurasia SS, Lim RR, Parikh BH, Wey YS, Tun BB, Wong TY, Luu CD, Agrawal R, Ghosh A, Mortellaro A, Rackoczy E, Mohan RR, Barathi VA (2018) The NLRP3 Inflammasome may contribute to pathologic neovascularization in the advanced stages of diabetic retinopathy. Sci Rep 8(1):2847CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Davidson JO, Green CR, Bennet L, Nicholson LF, Danesh-Meyer H, O'Carroll SJ, Gunn AJ (2013) A key role for connexin hemichannels in spreading ischemic brain injury. Curr Drug Targets 14(1):36–46CrossRefPubMedGoogle Scholar
  47. 47.
    Guo ZL, Yu SH, Chen X, Ye RD, Zhu WS, Liu XF (2016) NLRP3 is involved in ischemia/reperfusion injury. Cns Neurol Disord-Dr 15(6):699–712CrossRefGoogle Scholar
  48. 48.
    Ildefonso CJ, Biswal MR, Ahmed CM, Lewin AS (2016) The NLRP3 Inflammasome and its role in age-related macular degeneration. In: Retinal degenerative diseases. Springer, Berlin, pp 59–65CrossRefGoogle Scholar
  49. 49.
    Loukovaara S, Piippo N, Kinnunen K, Hytti M, Kaarniranta K, Kauppinen A (2017) NLRP3 inflammasome activation is associated with proliferative diabetic retinopathy. Acta Ophthalmol 95:803–808CrossRefPubMedGoogle Scholar
  50. 50.
    Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J (2010) Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 11(2):136–140CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Buchanan Ocular Therapeutics Unit, Department of Ophthalmology and the New Zealand National Eye CentreUniversity of AucklandAucklandNew Zealand
  2. 2.Department of Ophthalmology and the New Zealand National Eye CentreUniversity of AucklandAucklandNew Zealand
  3. 3.School of Optometry and Vision Science and the New Zealand National Eye CentreUniversity of AucklandAucklandNew Zealand

Personalised recommendations